Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Shots:Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseasesAs per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global…

ByRidhi RastogiApril 4, 2025

INSIGHTS+

A Complete Account of EMA Approvals in 2024

Shots: In 2024, EMA approved around 53 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, vaccines, diagnostic agents, pneumology, nephrology, hepatology, ophthalmology, and endocrinology PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, &…

ByDipanshu DixitMarch 6, 2025

News

Takeda Partners with BridGene Biosciences to Identify Novel Small Molecules in Immunology and Neurology

Shots:Takeda has entered into strategic collaboration & licensing agreement with BridGene bioscience to identify novel small molecules in immunology & neurology As per the terms, Takeda will gain exclusive rights to develop & commercialize products arising from the deal in exchange for $46M including upfront & preclinical milestone, plus additional ~$770M in clinical…

ByRidhi RastogiFebruary 26, 2025

VIEWPOINTS

Infusing AI in Clinical Trials: Meri Beckwith from Lindus Health in Conversation with PharmaShots

Shots: Meri Beckwith, Co-Founder of Lindus Health engages in a striking conversation with PharmaShots Meri talks about bridging the gaps of clinical trials in CNS/Neurology by leveraging LLMs that are trained on nearly a million clinical trial protocols and simple machine learning models to monitor real-time clinical trial data Meri highlights the importance of multidisciplinary…

BySaurabh ChaubeyMay 8, 2024

INSIGHTS+

Know Your Investor (March Edition): Qiming Venture Partners

Shots:In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and HealthcareIn 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…

BySenior EditorMarch 26, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Shots:The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industryIn February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative ColitisPharmaShots has compiled a list of a total…

BySenior EditorMarch 20, 2024

INSIGHTS+

A Complete Account of EMA Approvals in 2023

Shots: In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology For…

BySenior EditorMarch 5, 2024

INSIGHTS+

A Complete Account of FDA Approvals in 2023

Shots: 2023 remained a year of notable approvals by the US FDA. Around 55 drugs were approved, by the US FDA in 2023 PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Neurology, and Hematology  For the complete report with analysis, reach out to us…

BySenior EditorFebruary 1, 2024

EVENTS

35th World Congress for Neurorehabilitation: New Advances in Neurorehabilitation

Conference Series is delighted to welcome you to attend the “35th World Congress for Neurorehabilitation” to be held in Amsterdam, Netherlands, from August 07-08, 2023. The exhilarating scientific program will focus on Clinical Neurology, Cognitive Neuroscience Neurorehabilitation, Neurosurgery, Psychiatry. The two days program will be filled with insightful presentations, engaging discussions, and networking opportunities. This…

BySenior EditorJuly 7, 2023

VIEWPOINTS

Jay Pathmanathan, Medical Director at Beacon Biosignals Shares Insights on EEG Neurobiomarkers for the Development of Precision Medicines in Neurology

Shots:Jay spoke about the role of AI-based EEG neurobiomarkers in the development of therapies to treat neurologic diseasesJay also talked about the use of the EEG analytics platform for dose determination clinical researchThe interview gives an understanding of Beacon Biosignals' vision to accelerate new treatment options for neurological and psychiatric diseasesSmriti: Throw…

BySenior EditorSeptember 27, 2022

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

A Complete Account of EMA Approvals in 2024

Takeda Partners with BridGene Biosciences to Identify Novel Small Molecules in Immunology and Neurology

Infusing AI in Clinical Trials: Meri Beckwith from Lindus Health in Conversation with PharmaShots

Know Your Investor (March Edition): Qiming Venture Partners

Insights+: EMA Marketing Authorization of New Drugs in February 2024

A Complete Account of EMA Approvals in 2023

A Complete Account of FDA Approvals in 2023

35th World Congress for Neurorehabilitation: New Advances in Neurorehabilitation

Jay Pathmanathan, Medical Director at Beacon Biosignals Shares Insights on EEG Neurobiomarkers for the Development of Precision Medicines in Neurology

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter